Tissue Regenix announces launch of DermaPure™ in the USA
- DermaPure™ targets $1.4 billion a year market for skin substitutes
- Distribution network now covers 80% of country
- Federal institution distributor appointed
Tissue Regenix Group plc (AIM:TRX) (“Tissue Regenix” or “the Group”), the regenerative medical devices company, today announces that it has launched DermaPure™ (“DermaPure”) its decellularised dermis product in the US. Tissue Regenix’s partner CTS (Community Tissue Services) will begin shipping product to customers next week.
In addition to the launch of DermaPure™, the Group also announces that it has continued to expand its distribution network around the country and currently has a network of over 60 reps that covers 80% of the US. Through this network, sale representatives will actively promote Tissue Regenix’s dCELL® human dermis in acute care hospitals, Veteran Affairs (VA) Hospitals and institutions, as well as in Long Term Acute Care hospitals (LTACs).
Furthermore, Tissue Regenix has also signed an exclusive government supplier partnership with TASSMA for the distribution of DermaPure™. TASSMA provides business development services to medical device and equipment manufacturers seeking to rapidly grow their federal government market share. The partnership with TASSMA will allow Tissue Regenix to immediately target the Department of Veteran’s Affairs Healthcare System and the numerous branches of the US military.
The commercial launch of the DermaPure™ dermis allograft will now allow Tissue Regenix to target a market worth $1.4bn a year for wound healing devices and equipment. 6.5 million US patients are afflicted by chronic wounds currently.
Tissue Regenix’s DermaPure™ works by taking human donor skin and removing the DNA and cells, using the patented dCELL® process to leave a natural biological scaffold that can be placed in the wound to aid natural healing by attracting the patient’s own cells to the wound area.
A trial in the UK has shown that patients who have had chronic wounds for an average of 4½ years and who were treated with a single application of Tissue Regenix’ DermaPure™ have seen an 87% reduction in the size of all wounds, while 60% of patients were completely healed, with virtually no recurrences.
DermaPure™ can be easily administered in hospital and/or community settings, such as GP clinics, and is stored at room temperature, requiring no rehydration before use or expensive refrigerated storage.
Commercial production and distribution of the DermaPure™ is a significant step forward for Tissue Regenix. This paves the way for the development of other human tissue based medical treatments.
DermaPure™ is initially being targeted at acute care patients with diabetic foot ulcers, a condition which affects around 600,000 people in the US each year, and patients with venous leg ulcers, which currently affect around 2.5 million people in the US. We see this as a large market that is in need of medical innovation, which is exactly what DermaPure™ provides.
Tissue Regenix has managed to establish the US organisation and launch its first product less than 18 months after forming our North American subsidiary company, and we are now fully established and ready to demonstrate the commercial power of dCELL®. We look forward to continuing to progress the commercialisation of our unique technology.